NetworkNewsBreaks – Concert Pharmaceuticals Inc. (NASDAQ: CNCE) Featured in Mizuho Securities Research Report
Concert Pharmaceuticals Inc. (NASDAQ: CNCE) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “We hosted investor calls with Concert management last week following the company's end-of-Phase 2 meeting with FDA for CTP-543. Phase 3 trials are expected to begin in 4Q20, and we estimate top-line data could be available in 2022. We continue to see significant value in CNCE shares based on under-appreciated pipeline potential. We believe positive Phase 2 data from CTP-692 in schizophrenia (which we expect in 1Q21) could be transformational for the company: 1) validating the potential in…







